Pieris Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands	At the Market Offering [Member] Preferred Stock [Member]	At the Market Offering [Member] Common Stock [Member]	At the Market Offering [Member] Receivables from Stockholder [Member]	At the Market Offering [Member] Additional Paid-in Capital [Member]	At the Market Offering [Member] AOCI Attributable to Parent [Member]	At the Market Offering [Member] Retained Earnings [Member]	At the Market Offering [Member]	Private Placement [Member] Preferred Stock [Member]	Private Placement [Member] Common Stock [Member]	Private Placement [Member] Receivables from Stockholder [Member]	Private Placement [Member] Additional Paid-in Capital [Member]	Private Placement [Member] AOCI Attributable to Parent [Member]	Private Placement [Member] Retained Earnings [Member]	Private Placement [Member]	Conversion of Preferred Stock [Member] Preferred Stock [Member]	Conversion of Preferred Stock [Member] Common Stock [Member]	Conversion of Preferred Stock [Member] Receivables from Stockholder [Member]	Conversion of Preferred Stock [Member] Additional Paid-in Capital [Member]	Conversion of Preferred Stock [Member] AOCI Attributable to Parent [Member]	Conversion of Preferred Stock [Member] Retained Earnings [Member]	Conversion of Preferred Stock [Member]	Conversion of Preferred Stock [Member] Preferred Stock [Member]	Conversion of Preferred Stock [Member] Common Stock [Member]	Conversion of Preferred Stock [Member] Receivables from Stockholder [Member]	Conversion of Preferred Stock [Member] Additional Paid-in Capital [Member]	Conversion of Preferred Stock [Member] AOCI Attributable to Parent [Member]	Conversion of Preferred Stock [Member] Retained Earnings [Member]	Conversion of Preferred Stock [Member]	Conversion of Series E Preferred Stock [Member] Preferred Stock [Member]	Conversion of Series E Preferred Stock [Member] Common Stock [Member]	Conversion of Series E Preferred Stock [Member] Receivables from Stockholder [Member]	Conversion of Series E Preferred Stock [Member] Additional Paid-in Capital [Member]	Conversion of Series E Preferred Stock [Member] AOCI Attributable to Parent [Member]	Conversion of Series E Preferred Stock [Member] Retained Earnings [Member]	Conversion of Series E Preferred Stock [Member]	Preferred Stock [Member]	Common Stock [Member]	Receivables from Stockholder [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2020																																				14	56,003
Balance at Dec. 31, 2020																																				$ 0	$ 56	$ 0	$ 242,672	$ (295)	$ (211,406)	$ 31,027
Net loss																																				0	0	0	0	0	(36,206)	(36,206)
Foreign currency translation adjustment																																				0	0	0	0	911	0	911
Stock based compensation expense																																				$ 0	$ 0	0	3,895	0	0	3,895
Issuance of common stock resulting from exercise of stock options (in shares)																																				0	412
Issuance of common stock resulting from exercise of stock options																																				$ 0	$ 0	0	858	0	0	858
Issuance of common stock (in shares)	0	7,558						0	7,290
Issuance of common stock	$ 0	$ 8	$ (1,814)	$ 35,328	$ 0	$ 0	$ 33,522	$ 0	$ 8	$ 0	$ 18,905	$ 0	$ 0	$ 18,913
Issuance of common stock resulting from purchase of employee stock purchase plan shares (in shares)																																				0	40
Issuance of common stock resulting from purchase of employee stock purchase plan shares																																				$ 0	$ 0	0	96	0	0	96
Issuance of common stock resulting from exercise of warrants (in shares)																																				0	1,391
Issuance of common stock resulting from exercise of warrants																																				$ 0	$ 1	0	836	0	0	837
Issuance of common stock resulting from conversion of stock (in shares)																						(4)								(5,000)
Issuance of common stock resulting from conversion of stock																						$ 0	$ 4	$ 0	$ (4)	$ 0	$ 0	$ 0	$ 0	$ (5)	$ 0	$ 5	$ 0	$ 0	$ 0
Conversion of Stock, Shares Issued (in shares)																							3,812						5
Balance (in shares) at Sep. 30, 2021																																				16	71,505
Balance at Sep. 30, 2021																																				$ 0	$ 72	(1,814)	302,591	616	(247,612)	53,853
Balance (in shares) at Jun. 30, 2021																																				16	66,679
Balance at Jun. 30, 2021																																				$ 0	$ 67	0	277,496	234	(231,076)	46,721
Net loss																																				0	0	0	0	0	(16,536)	(16,536)
Foreign currency translation adjustment																																				0	0	0	0	382	0	382
Stock based compensation expense																																				$ 0	$ 0	0	1,370	0	0	1,370
Issuance of common stock resulting from exercise of stock options (in shares)																																				0	272
Issuance of common stock resulting from exercise of stock options																																				$ 0	$ 0	0	566	0	0	566
Issuance of common stock (in shares)	0	4,554
Issuance of common stock	$ 0	$ 5	(1,814)	23,159	0	0	21,350
Balance (in shares) at Sep. 30, 2021																																				16	71,505
Balance at Sep. 30, 2021																																				$ 0	$ 72	(1,814)	302,591	616	(247,612)	53,853
Balance (in shares) at Dec. 31, 2021																																				16	72,222
Balance at Dec. 31, 2021																																				$ 0	$ 72	0	306,998	829	(257,144)	50,755
Net loss																																				0	0	0	0	0	(25,175)	(25,175)
Foreign currency translation adjustment																																				0	0	0	0	(387)	0	(387)
Stock based compensation expense																																				$ 0	$ 0	0	3,453	0	0	3,453
Issuance of common stock resulting from exercise of stock options (in shares)																																				0	46
Issuance of common stock resulting from exercise of stock options																																				$ 0	$ 0	0	95	0	0	95
Issuance of common stock (in shares)	0	2,069
Issuance of common stock	$ 0	$ 2	0	6,838	0	0	6,840
Unrealized loss on investments															$ 0	$ 0	$ 0	$ 0	$ 82	$ 0	$ 82
Issuance of common stock resulting from purchase of employee stock purchase plan shares (in shares)																																				0	69
Issuance of common stock resulting from purchase of employee stock purchase plan shares																																				$ 0	$ 0	0	104	0	0	104
Issuance of common stock resulting from conversion of stock (in shares)																0
Conversion of Stock, Shares Issued (in shares)															0
Balance (in shares) at Sep. 30, 2022																																				16	74,406
Balance at Sep. 30, 2022																																				$ 0	$ 74	0	317,488	524	(282,319)	35,767
Balance (in shares) at Jun. 30, 2022																																				16	74,257
Balance at Jun. 30, 2022																																				$ 0	$ 74	0	316,249	625	(272,583)	44,365
Net loss																																				0	0	0	0	0	(9,736)	(9,736)
Foreign currency translation adjustment																																				0	0	0	0	(31)	0	(31)
Stock based compensation expense																																				0	0	0	974	0	0	974
Issuance of common stock (in shares)	0	0
Issuance of common stock																																				$ 0	$ 0	0	265	0	0	265
Unrealized loss on investments	$ 0	$ 0	$ 0	$ 0	$ (70)	$ 0	$ (70)
Balance (in shares) at Sep. 30, 2022																																				16	74,406
Balance at Sep. 30, 2022																																				$ 0	$ 74	$ 0	$ 317,488	$ 524	$ (282,319)	$ 35,767